|AHFS/Drugs.com||International Drug Names|
|Oral (tablets), IV|
|ATC code||R03AC06 (WHO) R03CC05 (WHO)|
|Bioavailability||5–11% (Tmax = 2 hours)|
|Metabolism||COMT (slow O-methylation)|
|Biological half-life||~50 minutes (if taken orally)|
|Chemical and physical data|
|Molar mass||420.499 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Hexoprenaline (HEX-oh-PREN-a-leen, INN) is a selective β2 adrenergic receptor agonist used in the treatment of asthma. Hexoprenaline is also used in some countries (such as Russia) as a tocolytic agent (i.e., labor suppressant), with the most common trade name being Gynipral. It is not approved by U.S. FDA.
When used as a tocolytic, hexoprenaline is contraindicated in:
- Cardiovascular diseases, e.g. cardiac arrhythmias, tachycardia, myocarditis, mitral valve disease and aortic stenosis
- Ischemic heart disease
- Angle-closure glaucoma
- Placental abruption, vaginal bleeding and inflammatory diseases of internal genitalia (such as endometritis)
- First trimester of pregnancy
It should be used with caution in people with gestational diabetes.
When concomitantly administered:
- Beta blockers reduce or neutralize therapeutic effects of hexoprenaline
- Methylxanthines (caffeine, theobromine, theophylline) increase its action
- General anaesthetics (e.g., halothane) and adrenergic receptor agonists may increase the risk of cardiovascular side effects, such as arrhythmia
- "Gynipral (hexoprenaline) Full Prescribing Information". Russian State Register of Medicinal Products (in Russian). Nycomed Austria GmbH. St. Peter-Straße 25, A-4020, Linz, Austria. Retrieved 19 March 2016.
- Pinder, RM; Brogden, RN; Speight, ™; Avery, GS (July 1977). "Hexoprenaline". Drugs. 14 (1): 1–28. doi:10.2165/00003495-197714010-00001. PMID 195789.
- "Gynipral (hexoprenaline) Tablets 0.5 mg, Solution for Intravenous Infusion 5 μg/mL (0.0005%)". "RLS" (РЛС): Russian Register of Medical Products (in Russian). Retrieved 19 March 2016.